Back to News
research

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Dyadic International reported its Q4 2025 earnings on March 25, 2026, highlighting biopharmaceutical advancements and financial performance for the year ending December 31, 2025. CEO Mark Emalfarb outlined progress in the company’s proprietary C1 protein expression platform, emphasizing its potential for accelerating drug development and reducing production costs. President Joe Hazelton detailed strategic shifts, including expanded partnerships with pharmaceutical firms and increased R&D investments to scale the C1 platform’s commercial applications. CFO Ping Rawson presented financial results, noting revenue growth driven by licensing agreements but warning of continued losses due to high R&D expenditures. The call included forward-looking statements about upcoming clinical trials and regulatory milestones, with disclaimers about potential risks and uncertainties in biotech innovation.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (30).png
Quantum News · Media Library

SA Transcripts159.12K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call March 25, 2026 5:00 PM EDT Company Participants Ping Rawson - Chief Financial OfficerJoseph Hazelton - President & COOMark Emalfarb - Founder, CEO & Director Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research DivisionJohn Vandermosten - Zacks Small-Cap ResearchTony Bowers Presentation Operator Good evening, and welcome to Dyadic International Full Year 2025 Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, March 25, 2026. I would now like to turn the call over to Mrs. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead. Ping RawsonChief Financial Officer Thank you, operator. Good evening, and welcome, everyone, to Dyadic's Full Year 2025 Conference Call. I hope you have had the opportunity to review Dyadic's press releases announcing financial results for the year ended December 31, 2025. You may access our release and Form 10-K under the Investors section of the company's website at dyadic.com. On today's call, our President and Chief Operating Officer, Joe Hazelton, will review our full year 2025 business and corporate highlights and provide a commentary on the strategic direction of the business. Our CEO, Mark Emalfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail, after which we'll hold a brief Q&A session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause Dyadic's actual results, performance, scientific or otherwise or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forward-looking statements, whether because of new information, future events or otherwise. Participants are directed to

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.